VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 30, 2006--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, announced that shareholders attending its January 19 meeting overwhelmingly approved an increase in capital that may be used to fund continued research and development of the Company's unique coatings for the multibillion-dollar worldwide vascular stent and drug-delivery markets.

ADVERTISEMENT

"In the last year, MIVT's scientific, administrative and executive teams have made great strides in moving toward commercialization of the Company's line of unique and proprietary biocompatible coatings for the biomedical marketplace," said Alan Lindsay, President and CEO of MIVT. "As we have reported, researchers have made excellent progress to develop a novel hydroxyapatite-based technology to create ultra-thin coatings for passive and drug-eluting applications for vascular stents."

Shareholders, by proxy or by attending MIVT's meeting of stockholders, held January 19 at the Company's corporate headquarters, approved an increase of MIVT shares to a total of 140 million common shares to fund the Company's continued strategic initiatives, including research and development. MIVT is looking forward to the coming year, and to making continued significant progress to commercialize our HAp-based, biocompatible coating technology for vascular stents and other implantable medical devices. MIVT's HAp-based technology and development programs have been validated during the last 12 months in a number of venues, including research results, and by scientific leaders and key observers in the biomedical community, who have singled out MIVT's solutions for special recognition.

Stents are used to prop open clogged or narrowed arteries and restore healthy blood flow, and other medical devices, but many current stent technologies are associated with serious complications that interfere with their success, such as restenosis, or re-narrowing of arteries following stent implantation. However, ongoing medical research has demonstrated that the Company's HAp coating formulations do not trigger the adverse reactions which are associated with existing stent products and technologies.

About MIV Therapeutics

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug-eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug-eluting coatings currently in the stent market. The Company's drug-eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

MIV Therapeutics, Inc.
Investor Relations, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
investor@mivtherapeutics.com
http://www.mivtherapeutics.com/
or 
for Product Inquiries and Business Opportunities:
Arc Rajtar, 604-301-9545 Ext. 22
arajtar@mivi.ca
or
Trilogy Capital Partners
Paul Karon, Toll-free: 800-342-1467
paul@trilogy-capital.com